Target Protein Degradation Market Size and Share by 2030

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. 

Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments:

Type of payment of licensing agreements

  • Upfront payments
  • Milestone payments

Type of protein degrader

  • Degronimids
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders

Therapeutic area

  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

Route of administration  

  • Oral
  • Intravenous
  • Other routes

Key geographical region

  • North America
  • Europe
  • Asia-Pacific

Get Detailed Analysis: 

Also Visit Our Latest Publication

HER2 Targeting Therapies Market

Solar Tracker Market

North America Telecom Power Systems Market

Nephrotic Syndrome Market

Erythropoietic Protoporphyria Market

This post was created with our nice and easy submission form. Create your post!

What do you think?

-9 Points
Upvote Downvote

Posted by Stella Wilson


Leave a Reply

Your email address will not be published. Required fields are marked *



How to Develop an Online Travel Portal Using White Label

طريقة عمل البرجر في البيت بسهولة للأطفال (والوصفات المختلفة لها)